Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Adaptimmune Therapeutics Plc ADR’s current trading price is -57.07% away from its 52-week high, while its distance from the 52-week low is 109.55%. The stock’s price range over this period has fluctuated between $0.42 and $2.05. The company, operating within the financial sector, had a trading volume of approximately 1.15 million for the day, which was noticeably lower than the average daily share volume of 1.75 million over the last 3 months.
Adaptimmune Therapeutics Plc ADR’s market performance has been stable in recent times. The company’s stock hit a 1-year high of $2.05 on 03/08/24 and a low of $0.42 for the same time frame on 11/28/23.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Adaptimmune Therapeutics Plc ADR (ADAP) has experienced a quarterly decline of -13.72% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 225.04M and boasts a workforce of 449 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.0937, with a change in price of -0.2580. Similarly, Adaptimmune Therapeutics Plc ADR recorded 1,762,451 in trading volume during the last 100 days, posting a change of -22.63%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for ADAP stands at 0.49. Similarly, the long-term debt-to-equity ratio is also 0.44.
ADAP Stock Stochastic Average
Today, Adaptimmune Therapeutics Plc ADR’s raw stochastic average for the past 50 days stands at 1.76%, indicating a decline from the raw stochastic average of the last 20 days, which was 3.36%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 11.85% and 16.36% respectively.
ADAP Stock Price Performance Analysis
The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. Year to date metric has recorded a gain of 10.98%.However, over the last six months, we can see a stronger performance of -36.22%. Over the last 30 days, the price of ADAP has leaped by -27.26%. And in the last five days, it has fallen by -4.26%.
